» Articles » PMID: 23562983

Minocycline, Levodopa and MnTMPyP Induced Changes in the Mitochondrial Proteome Profile of MPTP and Maneb and Paraquat Mice Models of Parkinson's Disease

Overview
Specialties Biochemistry
Biophysics
Date 2013 Apr 9
PMID 23562983
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondrial dysfunction is the foremost perpetrator of the nigrostriatal dopaminergic neurodegeneration leading to Parkinson's disease (PD). However, the roles played by majority of the mitochondrial proteins in PD pathogenesis have not yet been deciphered. The present study investigated the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and combined maneb and paraquat on the mitochondrial proteome of the nigrostriatal tissues in the presence or absence of minocycline, levodopa and manganese (III) tetrakis (1-methyl-4-pyridyl) porphyrin (MnTMPyP). The differentially expressed proteins were identified and proteome profiles were correlated with the pathological and biochemical anomalies induced by MPTP and maneb and paraquat. MPTP altered the expression of twelve while combined maneb and paraquat altered the expression of fourteen proteins. Minocycline, levodopa and MnTMPyP, respectively, restored the expression of three, seven and eight proteins in MPTP and seven, eight and eight proteins in maneb- and paraquat-treated groups. Although levodopa and MnTMPyP rescued from MPTP- and maneb- and paraquat-mediated increase in the microglial activation and decrease in manganese-superoxide dismutase expression and complex I activity, dopamine content and number of dopaminergic neurons, minocycline defended mainly against maneb- and paraquat-mediated alterations. The results demonstrate that MPTP and combined maneb and paraquat induce mitochondrial dysfunction and microglial activation and alter the expression of a bunch of mitochondrial proteins leading to the nigrostriatal dopaminergic neurodegeneration and minocycline, levodopa or MnTMPyP variably offset scores of such changes.

Citing Articles

Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism.

Buneeva O, Medvedev A Int J Mol Sci. 2025; 26(3).

PMID: 39941014 PMC: 11818313. DOI: 10.3390/ijms26031248.


Protopanaxadiols Eliminate Behavioral Impairments and Mitochondrial Dysfunction in Parkinson's Disease Mice Model.

Zhao J, Wang J, Zhao K, Zhang Y, Hu W Neurochem Res. 2024; 49(7):1751-1761.

PMID: 38551796 PMC: 11144128. DOI: 10.1007/s11064-024-04132-w.


Proteins and Transcriptional Dysregulation of the Brain Extracellular Matrix in Parkinson's Disease: A Systematic Review.

Rike W, Stern S Int J Mol Sci. 2023; 24(8).

PMID: 37108598 PMC: 10138539. DOI: 10.3390/ijms24087435.


Insights into Manganese Superoxide Dismutase and Human Diseases.

Liu M, Sun X, Chen B, Dai R, Xi Z, Xu H Int J Mol Sci. 2022; 23(24).

PMID: 36555531 PMC: 9786916. DOI: 10.3390/ijms232415893.


The Interplay between Gut Microbiota and Parkinson's Disease: Implications on Diagnosis and Treatment.

Varesi A, Campagnoli L, Fahmideh F, Pierella E, Romeo M, Ricevuti G Int J Mol Sci. 2022; 23(20).

PMID: 36293176 PMC: 9603886. DOI: 10.3390/ijms232012289.